BI and GSK to co-package HIV drugs

18 July 2004

Germany's Boehringer Ingelheim and UK drug major GlaxoSmithKline havesigned a letter of intent for an accelerated development program for a co-package of Viramune (nevirapine) and Combivir (lamivudine/zidovudine) for the treatment of HIV infection in the developing world.

"The co-package of Viramune and Combivir is the most expeditious strategy for facilitating access to HIV treatment in the developing world," said Alessandro Banchi, chairman of the board of managing directors at BI. "In practice, the Viramune-Combivir co-package will facilitate distribution and delivery of a recognised triple therapy to patients in need," he added.

The Viramune and Combivir combination regimen is already a well-established treatment for HIV which is recommended as a first-line therapy by the World Health Organization in its guidelines for developing countries (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight